SCHEMBL22124591

SCHEMBL22124591

COc1ccc(-c2cnc3c(Nc4ccc(C(=O)N(C)CCOCCN5CCN(C6COC6)CC5)c(C)c4)nccn23)cc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPKAPK5 Q8IW41 2/20 0.41
▸ TTK P33981 6/20 0.38
▸ PTK6 Q13882 2/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ SYK P43405 3/20 0.34
▸ AURKB Q96GD4 1/20 0.34
▸ FGFR4 P22455 1/20 0.34
▸ ZAP70 P43403 1/20 0.34
▸ AXL P30530 2/20 0.33
▸ CD63 P08962 1/20 0.33
▸ STK10 O94804 1/20 0.33
▸ CSF1R P07333 1/20 0.33
▸ RET P07949 1/20 0.33
▸ PDGFRB P09619 1/20 0.33
▸ KIT P10721 1/20 0.33
▸ FLT1 P17948 1/20 0.33
▸ TIE1 P35590 1/20 0.33
▸ FLT4 P35916 1/20 0.33
▸ FLT3 P36888 1/20 0.33
▸ TEK Q02763 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30349964 1.00 MAPKAPK5 (0.41) MAPKAPK5TTKPTK6MAPK1SYK
SCHEMBL22124676 0.95 TTK (0.39) MAPKAPK5TTKPTK6MAPK1SYK
SCHEMBL24916702 0.92 MAPKAPK5 (0.47) MAPKAPK5TTKPTK6MAPK1AURKB
SCHEMBL22124669 0.91 MAPKAPK5 (0.40) MAPKAPK5TTKPTK6MAPK1SYK
SCHEMBL24917117 0.90 PTK6 (0.44) MAPKAPK5TTKPTK6SYKAURKB
SCHEMBL22124685 0.89 MAPKAPK5 (0.40) MAPKAPK5TTKPTK6MAPK1SYK
SCHEMBL22125014 0.88 MAPKAPK5 (0.42) MAPKAPK5TTKPTK6SYKAURKB
SCHEMBL30349738 0.88 MAPKAPK5 (0.42) MAPKAPK5TTKPTK6SYKAURKB
SCHEMBL22125420 0.87 PTK6 (0.38) MAPKAPK5TTKPTK6SYKAURKB
SCHEMBL24112349 0.87 MAPKAPK5 (0.41) MAPKAPK5TTKPTK6SYKAURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3898630-B1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2023-05-10 — — EP claimed
EP-3898630-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2021-10-27 — — EP claimed
WO-2020126954-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2020-06-25 — — WO claimed
EP-3898630-B1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN LA ROCHE (CH) 2023-05-10 — — EP disclosed
US-20230017532-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2023-01-19 — — US disclosed
EP-3898630-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES F. Hoffmann-La Roche AG (CH) 2021-10-27 — — EP disclosed
WO-2020126954-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2020-06-25 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230017532-A1 NOVEL IMIDAZOPYRAZINE DERIVATIVES MRPL21, O60361, MYD88 MAPKAPK5 695/4885TTK 4573/4885PTK6 2141/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback